Cis-Diamminedichloride Platinum II in the Treatment of Abvanced Bladder Cancer

Abstract

Patients (21) with advanced, measurable bladder cancer were treated with cis-diamminedichloride platinum II. Of the 21 patients, 3 (14%) achieved a complete response that persisted for more than 1 yr, 6 (29%) achieved a partial remission for an average duration of 5.7 mo. Responses to cis-diamminedichloride platinum II were noted shortly after administration of the drug. After the initial response, no additional benefit of cis-diamminedichloride platinum II was observed after 9 wk (3rd dose). Despite the fact that cis-diamminedichloride platinum II was tolerated reasonably well by the majority of patients and that there were 3 cases of long-term remission, cis-diamminedichloride platinum II appears limited to induction of a response in patients with advanced bladder cancer rather than for long-term maintenance therapy.